Company Description
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients.
The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program.
The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2005 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | John K. Celebi M.B.A. |
Contact Details
Address: 1405 Research Blvd, Suite 125 Rockville, Maryland 20850 United States | |
| Phone | (240) 243-8000 |
| Website | senseibio.com |
Stock Details
| Ticker Symbol | SNSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001829802 |
| CUSIP Number | 81728A108 |
| ISIN Number | US81728A1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John K. Celebi M.B.A. | President, Chief Executive Officer and Director |
| Dr. Edward Van der Horst Ph.D. | Chief Scientific Officer |
| Lora Pike | Vice President of Investor Relations and Communications |
| Christopher W. Gerry J.D. | Senior Vice President, General Counsel and Secretary |
| Stephanie Krebs M.B.A., M.S. | Chief Business Officer |
| Dr. Aaron Weitzman FACP, M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 8, 2024 | 8-K | Current Report |
| Jan 4, 2024 | 8-K | Current Report |